(122)Se tabel 8 OL: Tilbud om frivillig hiv-rådgivning og testning samt behandling (onlineversion).(123)Stærkt aktiv anti-retrovirbehandling.(124)Se tabel 9 OL: Tilbud om hepatitis B-vaccination (HBV) for injektionsmisbrugere i nogle europæiske lande (onlineversion).(125)Se tabel 10 OL: Behandling af intravenøse stofbrugere, som er smittet med hepatitis C (onlineversion).(126)Mistet levetid i år: baseret på den alder, enhver person ville forventes at leve, hvis han eller hun ikke var død som følge af narkotikabrug (ACMD, 2000, s. 56).
)See Table 7 OL: Provision and types of syringeexchange programmes (SEPs), pharmacy involvement, numbers of syringes distributed/sold (2001 data are presented in Table 8 OL of the 2002 annual report at: http://ar2002.emcdda.eu.int/en/popups/oltab08-en.html).(122)See Table 8 OL: Provision of HIV voluntary counselling and testing (VCT) and treatment (online version).(123)Highly active antiretroviral treatment.(124)See Table 9 OL: Provision of hepatitis B virus (HBV) vaccination for injecting drug users (IDUs) in some European countries (online version).(125)See Table 10 OL: Treatment for hepatitis C-infected injecting drug users (IDUs) (online version).(126)Years of life lost: based on the age to which any individual would be expected to live if he or she had not died as a result of drug use (ACMD, 2000, p.56).